• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home StudyGraphics

#VisualAbstract: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

byConstance Wu
November 30, 2019
in StudyGraphics
Reading Time: 2 mins read
#VisualAbstract: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Share on FacebookShare on TwitterShare on LinkedIn

1. In this phase 3 trial, patients with relapsed or refractory acute myeloid leukemia who received gilteritinib had a longer median overall survival and a higher likelihood of complete remission versus chemotherapy. After factoring in therapy duration, serious adverse events also occurred less frequently in the gilteritinib group.

2. Despite these statistically significant improvements, long-term survival remained poor, indicating the need for further research into the timing and toxicity of intervention.

Evidence Rating Level: 1 (Excellent)

Study Rundown: FMS-like tyrosine kinase 3 (FLT3) is involved in the proliferation and differentiation of hematopoietic stem cells. When constitutively activated through mutation as in roughly 30% of patients with acute myeloid leukemia (AML), the enzyme sparks uncontrolled growth and adversely affects survival. Given the ineffectiveness of salvage chemotherapy as a second-line treatment for AML that is refractory to standard chemotherapy, FLT3 inhibitors have been a welcome addition to the arsenal of treatment options. However, issues have arisen with their selectivity and single-agent potency, stressing the continued need for a powerful molecule that demonstrates strong activity against both mutation subtypes (ITD and TKD) yet spares other essential kinases. This randomized study aimed to confirm the safety and efficacy of one such candidate, gilteritinib, in the treatment of relapsed or refractory FLT3-mutated AML. Patients treated with gilteritinib experienced both a longer median overall survival and a higher likelihood of complete remission with full or partial hematologic recovery compared to those who received salvage chemotherapy. The exposure-adjusted rate of adverse events of grade 3 or higher was also significantly lower in the gilteritinib group, with some of the most common events in both groups being febrile neutropenia, anemia, and thrombocytopenia. However, long-term survival rates remained poor in both groups. These promising findings beg further research into the timing of FLT3 intervention as well as its role in the grand scheme of potential treatments.

Click here to read the study in the NEJM (New England Journal of Medicine)

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

Quizartinib improves overall median survival in patients with acute myeloid leukemia

Tags: acute myeloid leukemiaFLT3 inhibitorsgilteritinibtyrosine kinase inhibitor
Previous Post

The Relationship between Health Care Provider Burnout and Quality of Patient Care

Next Post

#VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

RelatedReports

Chronic Disease

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

October 10, 2023
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Chronic Disease

Quizartinib improves overall median survival in patients with acute myeloid leukemia

May 25, 2023
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Chronic Disease

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

May 13, 2022
Next Post
#VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

#VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

Outcomes not improved with early amoxicillin-clavulanate in cardiac arrest patients

#VisualAbstract: Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping

#VisualAbstract: Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.